BeyondSpring Inc (BYSI) - Cash Flow Conversion Efficiency
Based on the latest financial reports, BeyondSpring Inc (BYSI) has a cash flow conversion efficiency ratio of 0.236x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-5.65 Million) by net assets ($-23.99 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
BeyondSpring Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how BeyondSpring Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of BeyondSpring Inc for a breakdown of total debt and financial obligations.
BeyondSpring Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of BeyondSpring Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
TsannKuen (China) Enterprise Co. Ltd
SHE:200512
|
-0.016x |
|
Commercial Vehicle Group Inc
NASDAQ:CVGI
|
-0.012x |
|
AGRONOMICS LTD.LS-0000001
F:V77
|
N/A |
|
Linz Textil Holding AG
VI:LTH
|
0.059x |
|
Lion Chemtech Co. Ltd
KQ:171120
|
0.119x |
|
Altinyag Kombinalari AS
IS:ALMAD
|
0.013x |
|
Pansar Bhd
KLSE:8419
|
0.206x |
|
T7 Global Bhd
KLSE:7228
|
0.023x |
Annual Cash Flow Conversion Efficiency for BeyondSpring Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of BeyondSpring Inc from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of BeyondSpring Inc.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-23.99 Million | $-20.02 Million | 0.835x | -27.49% |
| 2024-12-31 | $-14.29 Million | $-16.44 Million | 1.151x | +63.93% |
| 2023-12-31 | $-23.46 Million | $-16.47 Million | 0.702x | -92.50% |
| 2022-12-31 | $-3.01 Million | $-28.15 Million | 9.362x | +514.63% |
| 2021-12-31 | $20.92 Million | $-47.24 Million | -2.258x | -373.93% |
| 2020-12-31 | $91.82 Million | $-43.74 Million | -0.476x | +69.21% |
| 2019-12-31 | $31.13 Million | $-48.16 Million | -1.547x | -136.33% |
| 2018-12-31 | $-9.38 Million | $-39.95 Million | 4.259x | +514.63% |
| 2017-12-31 | $28.04 Million | $-28.80 Million | -1.027x | +7.78% |
| 2016-12-31 | $12.30 Million | $-13.70 Million | -1.114x | -63.72% |
| 2015-12-31 | $9.66 Million | $-6.57 Million | -0.680x | -657.57% |
| 2014-12-31 | $-9.39 Million | $-1.15 Million | 0.122x | -- |
About BeyondSpring Inc
BeyondSpring Inc., a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. It operates through two segments: Plinabulin pipeline and TPD platform. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-canc… Read more